Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ralph Lauren Corp RL

Consumer Cyclical Luxury Goods
Ralph Lauren Corporation is engaged in the design, marketing, and distribution of luxury lifestyle products, including apparel, footwear & accessories, home, fragrances, and hospitality. Its segments include North America, Europe, and Asia. Its brands include Ralph Lauren, Ralph Lauren Collection, Ralph Lauren Purple Label, Double RL, Polo Ralph Lauren, Lauren Ralph Lauren, Polo Ralph Lauren... see more

Recent & Breaking News (NYSE:RL)

Tarzana Dermatologist, Dr. Peyman Ghasri, is Now Offering Sclerotherapy

PR Newswire December 30, 2014

Dr. Stafford Broumand Reveals Benefit of Receiving Injectables From a Plastic Surgeon

Marketwired December 30, 2014

Palatin Announces Start of Bremelanotide Phase 3 Program For Female Sexual Dysfunction

PR Newswire December 29, 2014

Cellceutix Adds Dr. Daniel Jorgensen as Chief Medical Officer

Marketwired December 29, 2014

CEL-SCI Reports Fiscal 2014 Financial Results and Clinical & Corporate Developments

Business Wire December 23, 2014

BioLineRx Out-Licenses Novel Skin Lesion Treatment to Omega Pharma

Business Wire December 23, 2014

Christmas Gift to People Worldwide Suffering From "Flesh Eating" Disease: NovaBay Pharmaceuticals and the National Necrotizing Fasciitis Foundation Will Offer New Life- and Limb-Saving Treatment At No Charge to Patients Worldwide

Accesswire December 23, 2014

Dermatology Residents Test their Knowledge

PR Newswire December 22, 2014

Enhanced Equity Funds, LLC Invests in West Dermatology

PR Newswire December 22, 2014

Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease

Thomson Reuters ONE December 22, 2014

Sienna Labs Obtains Sixth Patent Relating to Use of Plasmonic Nanoparticles in Treatment of Sebaceous Glands and Hair

PR Newswire December 19, 2014

RXi Pharmaceuticals Expands its Clinical Pipeline with an Exclusive Global License for a Second Phase 2 Clinical Compound

PR Newswire December 19, 2014

Micro Market Monitor: North American Dermatology Diagnostic Devices Market

PR Newswire December 18, 2014

Tower Dental Group in Boca Raton, Florida Provides Patients with Expert Treatment and Cosmetic Procedures

PR Newswire December 18, 2014

Pediapharm and Uriach Enter Into a License and Supply Agreement for a Novel Product Developed to Efficiently Treat the Symptoms of Allergy and Urticaria in Both Adults and Children

Marketwired December 18, 2014

ZAPNE Acne Treatment System Applies 3 Tier Logic's Consumer-to-Consumer Content Marketing Platform to Drive Brand Awareness and Ignite Sales

Canada NewsWire December 18, 2014

Chronic Urticaria / Hives Therapeutic Pipeline H2 2014 Review Research Report

PR Newswire December 17, 2014

IBM Research Scientists Investigate Use of Cognitive Computing-Based Visual Analytics for Skin Cancer Image Analysis

PR Newswire December 17, 2014

Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus

PR Newswire December 17, 2014

Ipsen's Somatuline® Depot® is the First Therapy Approved by the FDA in the United States for the Treatment of Patients with Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumors

Business Wire December 16, 2014